Skip to main content

Advertisement

Log in

Establishment and characterization of a clear cell carcinoma cell line, designated NOCC, derived from human ovary

  • Cell Line
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

A cell line, designated NOCC, was established from the ascites of a patient with clear cell adenocarcinoma of the ovary. The cell line has been grown without interruption and continuously propagated by serial passaging (more than 76 times) over 7 years. The cells are spherical to polygonal-shaped, display neoplastic, and pleomorphic features, and grow in a jigsaw puzzle-like pattern while forming monolayers without contact inhibition. The cells proliferate rapidly, but are easily floated as a cell sheet. The population doubling time is about 29 h. The number of chromosomes ranges from 60 to 83. The modal number of chromosomes is 70–74 at the 30th passage. NOCC cells secreted 750.5 ng/ml of VEGF over 3 days of culture. Hypoxia inducible factor-1α (HIF-1α) is a primary regulator of VEGF under hypoxic conditions. NOCC cells were not sensitive to the anticancer drugs BEV, DOX, GEM, ETP, CDDP, or TXT. The graft of NOCC cells to a scid mouse displayed similar histological aspects to the original tumor. Both the NOCC cells and the graft of the NOCC cells gave a positive PAS reaction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Nozawa S, Tsukazaki K, Sakoyori M, et al. Establishment of a human clear cell carcinoma cell line (RMG-1) and its single cell cloning. Hum Cell. 1988;1:426–35.

    CAS  PubMed  Google Scholar 

  2. Wong WSF, Wong YF, Ng YT, Huang PD, Chew EC, Ho TH. Establishment and characterization of a new human cell line. Gynecol Oncol. 1990;38:37–45.

    Article  CAS  PubMed  Google Scholar 

  3. Nozawa S, Yajima M, Sasaki H, et al. A new 125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II). Jpn J Cancer. 1991;82:854–61.

    Article  CAS  Google Scholar 

  4. Yamada K, Tachibana T, Hashimoto H, et al. Establishment and characterization of cell lines derived from serous adenocarcinoma (JHOS-2) and clear cell carcinoma (JHOC-5, JHOC-6) of human ovary. Hum Cell. 1999;12:131–8.

    CAS  PubMed  Google Scholar 

  5. Aoki D, Suzuki N, Susumu N, et al. Establishment and characterization of the RMG-V cell line from human ovarian clear cell carcinoma. Hum Cell. 2005;18:143–6.

    Article  PubMed  Google Scholar 

  6. Saga Y, Suzuki M, Machida S. Establishment of a new cell line (TAYA) of clear cell adenocarcinoma of the ovary and its radiosensitivity. Oncology. 2002;62:180–4.

    Article  CAS  PubMed  Google Scholar 

  7. Ishiwata I, Ishiwata C, Soma M, et al. Establishment of HUOCA-II, a human ovarian clear cell adenocarcinoma cell line, and its angiogenic activity. J Natl Cancer Res. 1987;78:667–73.

    CAS  Google Scholar 

  8. Itomachi H, Kato M, Nishimura M. Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. Hum Cell. 2013;26:121–7.

    Article  Google Scholar 

  9. Scully RE. World Health Organization classification and nomenclature of ovarian cancer. Natl Cancer Inst Monogr. 1975;42:5–7.

    CAS  PubMed  Google Scholar 

  10. Aure JC, Hoeg K, Kolstad P. Mesonephroid tumors of the ovary. Clinical and histopathologic studies. Obstet Gynecol. 1971;37:860–7.

    CAS  PubMed  Google Scholar 

  11. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584–9.

    Article  CAS  PubMed  Google Scholar 

  12. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicenter experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94:1369–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Itomachi H, Kigawa J, Sugiyama T, et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol. 2002;100:281–7.

    Google Scholar 

  14. Enomoto T, Kuragaki C, Yamasaki M, et al. Is clear cell carcinoma and mucous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol. 2003;22:447.

    Google Scholar 

  15. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1β as a molecular marker and possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Tsukagoshi S, Saga Y, Suzuki N, et al. Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo. Int J Oncol. 2003;22:961–7.

    CAS  PubMed  Google Scholar 

  17. Semenza GL, Jiang BH, Leung SW, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996;271(51):32529–37.

    Article  CAS  PubMed  Google Scholar 

  18. Wenger RH, Kvietikova I, Rolfs A, et al. Hypoxia-inducible factor-1 alpha is regulated at the post-mRNA level. Kidney Int. 1997;51(2):560–3.

    Article  CAS  PubMed  Google Scholar 

  19. Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res. 2006;83(3):473–83.

    Article  CAS  PubMed  Google Scholar 

  20. Baby SM, Roy A, Mokashi AM, et al. Effects of hypoxia and intracellular iron chelation on hypoxia-inducible factor-1 alpha in the rat carotid body and glomus cells. Histochem Cell Biol. 2003;120(5):343–52.

    Article  CAS  PubMed  Google Scholar 

  21. Sang N, Fang J, Srinivas V, et al. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hoppel–Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol. 2002;22(9):2984–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Uesu K, Ishikawa H. Analysis of an in vitro susceptibility test of anticancer drugs using new types of oxygen electrodes. Bull Educ Res Nihon Univ Sch Dent Matsudo. 2005;7:7–21.

    Google Scholar 

Download references

Acknowledgments

This work was supported in part by a Grant-in-Aid for Scientific Research (B) [No. 20390501 (H.I.)], and a Grant-in-Aid for challenging Exploratory Researches [No. 26670908 and No. 22659314 (H.I.)].

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Akihiro Ohyama.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ohyama, A., Toyomura, J., Tachibana, T. et al. Establishment and characterization of a clear cell carcinoma cell line, designated NOCC, derived from human ovary. Human Cell 29, 188–196 (2016). https://doi.org/10.1007/s13577-016-0142-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-016-0142-x

Keywords

Navigation